Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBITDA (2024 - 2025)

Silence Therapeutics (SLN) has disclosed EBITDA for 2 consecutive years, with $56.5 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 18.0% to $56.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$22.2 million through Dec 2025, down 99.28% year-over-year, with the annual reading at -$22.2 million for FY2025, 99.26% down from the prior year.
  • EBITDA hit $56.5 million in Q4 2025 for Silence Therapeutics, up from -$26.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $56.5 million in Q4 2025 to a low of -$30.0 million in Q3 2024.